QTRX

Quanterix Corporation (QTRX) | Rumor.io

Quanterix

QTRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,921

Bullish sentiment (50-day avg)57%

Price to earnings ratio-1.41

Market capitalization166.5M

Earnings per share-2.62

Dividend yield (TTM)—

Revenue (annual)138.7M

Net income (annual)-107.2M

Social

What share of all stock conversation is about QTRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 10

Quanterix Corporation reported a 34% YoY GAAP revenue growth in Q2 2026, but pro-forma revenue actually declined 23% due to severe execution issues.
The company's Q2 results were met with disappointment, with a guidance cut of 15% and a delay in achieving cash flow breakeven until 2027.
Despite the weak quarter, the stock is considered undervalued, with a price-to-sales ratio of 0.10x, and some analysts believe the operating business is being sold for free, with cash valued at around $2 per share.

Generated by AI

Sentiment

Of the messages about QTRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +58.87	80.89% -15.68
Bearish	0%	0% 0	0% -58.87	19.11% +15.68

Bullish· Sep 27

$QTRX is undervalued and has room for upside, making it a good investment opportunity.
Token gating has been implemented, providing a new layer of utility and growth potential for the asset, and cross-chain support is expected to be huge.
The asset's low market capitalization, currently under $1 million, presents a good buying opportunity, and early buyers may see significant returns if the asset's potential is realized.

Bearish· Aug 9

The new CEO of Quanterix Corporation is struggling to address the company's problems, as evidenced by their inability to answer questions about the quality of assays during the earnings call.
The company's recent performance has been a major overreaction, with a 60% drop in stock price due to the firing of 25% of employees and the new CEO's inability to address the company's issues.
Quanterix Corporation's stock is trading at a level that is below its cash value, with some analysts considering it a "bargain" and a potential opportunity for a rebound in the coming days.

Generated by AI

Topics

Of the messages about QTRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	95.65%	97.67%	36.21%
Announcements	100%	4.35%	2.33%	35.8%
Analysts	0%	0%	0%	6.17%
Earnings	0%	0%	0%	21.81%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Earnings· May 9

Quanterix Corporation ($QTRX) reports Q1 net loss of $7.2M, beating on revenues.
Quanterix announces Q1 EPS of $0.33, missing estimates.
Quanterix's Q1 earnings results show a net loss, with revenue performance being a slight bright spot.

Analysts· Mar 2

Goldman Sachs upgraded Quanterix $QTRX to Neutral from Sell with a price target of $40.
JP Morgan maintained an Overweight rating for Quanterix $QTRX, but lowered its price target to $60 from $85.
SVB Leerink maintained an Outperform rating for Quanterix $QTRX, but lowered its price target to $50 from $70.

Announcements· Sep 19

Quanterix Corporation's native token $QTRX has launched on Ethereum mainnet, enabling governance, rewards, and full utility.
The token offers governance power, allowing holders to vote on agent upgrades and participate in airdrops from Myriad XP and Abstract points.
Quanterix has launched on DexScreener, providing real-time charts and liquidity tracking for $QTRX, and the company's app is expected to roll out soon.

Generated by AI

Community

Of the messages about QTRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.5%	28.13%	16.36%	30.87%
Newcomers	12.5%	71.88%	83.64%	69.13%

Regulars· Jan 11

The regular investor is cautiously optimistic about Quanterix Corporation, citing positive reviews of its new product line and potential synergies with the recently announced merger.
The investor notes that Quanterix's merger partner has a strong clinical focus, which could be a key driver of combined sales of around $220 million.
The regular investor suggests that Quanterix's market capitalization of around $600 million may be overvalued relative to its sales, potentially indicating a downward trend in the stock.

Newcomers· Aug 10

Quanterix Corporation's earnings report was disappointing, with revenue missing expectations by -$4.6M and a gross margin of 38.5% vs 40.9% a year ago.
The company's weak quarter and guidance cut led to a 50% price drop, but some investors see it as an overreaction, citing the company's low valuation and cash position.
Quanterix's recent price breakout and accumulation signals suggest a potential upside, with some analysts citing a measured move from the flag and a climbing RSI that supports further growth.

Generated by AI

BILLERICA, Mass., September 25, 2026--Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on th

5d agoYahoo Finance Singapore

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass., September 17, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the "Inducement Grants") were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units ("RSUs") representing 260,315 shares of Q

13d agoYahoo Finance

Quanterix appoints Yuri Fesko as chief medical officer

16d agoInvesting.com

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

BILLERICA, Mass., September 14, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company’s Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix’s innovative technologies and applications.

16d agoYahoo Finance

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Canaccord cuts Quanterix stock price target on weak Q2 results

1mo agoInvesting.com

Also Discussed

Investors talking about QTRX also mention

#	Name	Attention
1	Invesco S&P SmallCap 600 Pure Value ETFRZV	0%0
2	Armada Acquisition Corp. IIIAACIU	0%0
3	Leverage Shares 2X Long BBAI Daily ETFBAIG	0%0
4	HUDSON PACIFIC PROPERTIES INCHPP	0%new
5	Crane NXT, Co.CXT	0%0
6	Allogene Therapeutics IncALLO	0%new
7	Seer, Inc. Class A Common StockSEER	0%0
8	CNB Financial Corp.CCNE	0%new
9	ENTR - ERShares Entrepreneur ETF	——
10	Invesco NASDAQ Next Gen 100 ETFQQQJ	0%0

Quanterix Corporation

Healthcare
Medical Devices

Quanterix Corporation is a life sciences tools and diagnostics company that develops ultra-sensitive digital immunoassay platforms for research and clinical applications. Quanterix’s core products and services include the Simoa assay kits, automated analyzers, biomarker detection systems, imaging and analysis platforms, and laboratory services used to measure very low levels of proteins and other biomarkers in blood and related fluids. The company supports work across disease research, diagnostics, and drug development, helping laboratories and healthcare organizations generate precise biomarker data for scientific and clinical use. Quanterix serves customers in North America, Europe, the Middle East, Africa, and the Asia Pacific regions, with offerings used by academic researchers, biopharmaceutical companies, and clinical laboratories. Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix Corporation plays a specialized role in precision biomarker science and advanced diagnostic testing.

Website

Location

Building 1

Billerica, MA, 01821

United States

Social

What share of all stock conversation is about QTRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 10

Quanterix Corporation reported a 34% YoY GAAP revenue growth in Q2 2026, but pro-forma revenue actually declined 23% due to severe execution issues.
The company's Q2 results were met with disappointment, with a guidance cut of 15% and a delay in achieving cash flow breakeven until 2027.
Despite the weak quarter, the stock is considered undervalued, with a price-to-sales ratio of 0.10x, and some analysts believe the operating business is being sold for free, with cash valued at around $2 per share.

Generated by AI

Sentiment

Of the messages about QTRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +58.87	80.89% -15.68
Bearish	0%	0% 0	0% -58.87	19.11% +15.68

Bullish· Sep 27

$QTRX is undervalued and has room for upside, making it a good investment opportunity.
Token gating has been implemented, providing a new layer of utility and growth potential for the asset, and cross-chain support is expected to be huge.
The asset's low market capitalization, currently under $1 million, presents a good buying opportunity, and early buyers may see significant returns if the asset's potential is realized.

Bearish· Aug 9

The new CEO of Quanterix Corporation is struggling to address the company's problems, as evidenced by their inability to answer questions about the quality of assays during the earnings call.
The company's recent performance has been a major overreaction, with a 60% drop in stock price due to the firing of 25% of employees and the new CEO's inability to address the company's issues.
Quanterix Corporation's stock is trading at a level that is below its cash value, with some analysts considering it a "bargain" and a potential opportunity for a rebound in the coming days.

Generated by AI

Topics

Of the messages about QTRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	95.65%	97.67%	36.21%
Announcements	100%	4.35%	2.33%	35.8%
Analysts	0%	0%	0%	6.17%
Earnings	0%	0%	0%	21.81%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Earnings· May 9

Quanterix Corporation ($QTRX) reports Q1 net loss of $7.2M, beating on revenues.
Quanterix announces Q1 EPS of $0.33, missing estimates.
Quanterix's Q1 earnings results show a net loss, with revenue performance being a slight bright spot.

Analysts· Mar 2

Goldman Sachs upgraded Quanterix $QTRX to Neutral from Sell with a price target of $40.
JP Morgan maintained an Overweight rating for Quanterix $QTRX, but lowered its price target to $60 from $85.
SVB Leerink maintained an Outperform rating for Quanterix $QTRX, but lowered its price target to $50 from $70.

Announcements· Sep 19

Quanterix Corporation's native token $QTRX has launched on Ethereum mainnet, enabling governance, rewards, and full utility.
The token offers governance power, allowing holders to vote on agent upgrades and participate in airdrops from Myriad XP and Abstract points.
Quanterix has launched on DexScreener, providing real-time charts and liquidity tracking for $QTRX, and the company's app is expected to roll out soon.

Generated by AI

Community

Of the messages about QTRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.5%	28.13%	16.36%	30.87%
Newcomers	12.5%	71.88%	83.64%	69.13%

Regulars· Jan 11

The regular investor is cautiously optimistic about Quanterix Corporation, citing positive reviews of its new product line and potential synergies with the recently announced merger.
The investor notes that Quanterix's merger partner has a strong clinical focus, which could be a key driver of combined sales of around $220 million.
The regular investor suggests that Quanterix's market capitalization of around $600 million may be overvalued relative to its sales, potentially indicating a downward trend in the stock.

Newcomers· Aug 10

Quanterix Corporation's earnings report was disappointing, with revenue missing expectations by -$4.6M and a gross margin of 38.5% vs 40.9% a year ago.
The company's weak quarter and guidance cut led to a 50% price drop, but some investors see it as an overreaction, citing the company's low valuation and cash position.
Quanterix's recent price breakout and accumulation signals suggest a potential upside, with some analysts citing a measured move from the flag and a climbing RSI that supports further growth.

Generated by AI

Quanterix

Social

Aug 10

Bullish· Sep 27

Bearish· Aug 9

Earnings· May 9

Analysts· Mar 2

Announcements· Sep 19

Regulars· Jan 11

Newcomers· Aug 10

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix appoints Yuri Fesko as chief medical officer

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Canaccord cuts Quanterix stock price target on weak Q2 results

Also Discussed

Quanterix Corporation

Company Information

Location

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix appoints Yuri Fesko as chief medical officer

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Canaccord cuts Quanterix stock price target on weak Q2 results

Also Discussed

Social

Aug 10

Bullish· Sep 27

Bearish· Aug 9

Earnings· May 9

Analysts· Mar 2

Announcements· Sep 19

Regulars· Jan 11

Newcomers· Aug 10